GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBPP.PFD) » Definitions » Earnings per Share (Diluted)

RGBPP.PFD (Regen BioPharma) Earnings per Share (Diluted) : $0.00 (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Regen BioPharma Earnings per Share (Diluted)?

Regen BioPharma's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

Regen BioPharma's EPS (Basic) for the three months ended in Sep. 2024 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

Regen BioPharma's EPS without NRI for the three months ended in Sep. 2024 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

During the past 3 years, the average EPS without NRIGrowth Rate was 17.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 37.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 50.30% per year.

During the past 12 years, Regen BioPharma's highest 3-Year average EPS without NRI Growth Rate was 79.20% per year. The lowest was -16.60% per year. And the median was 29.70% per year.


Regen BioPharma Earnings per Share (Diluted) Historical Data

The historical data trend for Regen BioPharma's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Earnings per Share (Diluted) Chart

Regen BioPharma Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regen BioPharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regen BioPharma's Earnings per Share (Diluted)

For the Biotechnology subindustry, Regen BioPharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's PE Ratio falls into.



Regen BioPharma Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Regen BioPharma's Earnings Per Share (Diluted) for the fiscal year that ended in Sep. 2024 is calculated as

Diluted Earnings Per Share (A: Sep. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.867-0)/0
=

Regen BioPharma's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2024 is calculated as

Diluted Earnings Per Share (Q: Sep. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.265-0)/0
=

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Regen BioPharma  (OTCPK:RGBPP.PFD) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Regen BioPharma Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.